(Reuters) -The U.S. Food and Drug Administration has approved COVID-19 vaccines in the U.S. including mRNA-based shots from Moderna and Pfizer with partner BioNTech, as well as Novavax’s traditional protein-based shot.

Here are the details of the FDA’s approvals:

PFIZER/BIONTECH

Pfizer and BioNTech’s shot, Comirnaty, is fully approved for all adults 65 and older and individuals aged five through 64 years who are at increased risk of severe COVID-19 infection.

The FDA has pulled the emergency use approval for the shot in children under the age of 5.

MODERNA

Moderna’s vaccine, Spikevax, is approved for individuals 65 years of age and older and for those six months through 64 years of age who are at risk for severe disease.

The agency approved Moderna’s next-generation shot, mNEXSPIKE,

See Full Page